Latest News
Supporting those who care: Introducing the MPE Care Connect Programme
Myeloma Patients Europe (MPE) is proud to announce the launch of the Care Connect Programme, a new initiative dedicated to strengthening support for carers of people living with myeloma and AL amyloidosis across Europe. Carers play a vital role in the lives of patients, providing emotional support, practical assistance, care coordination, and advocacy throughout the myeloma pathway. However, feedback from MPE member organisations has…
EHA 2026 interviews and highlights
MPE at EHA 2026: Stockholm in review EHA 2026 brought thousands of researchers, clinicians and patient advocates together in Stockholm for four days of cutting-edge science, discussion and connection. For the MPE team, it was a week of in-depth learning and valuable exchanges with stakeholders. What we did Across the congress we attended myeloma scientific…
European Commission approves subcutaneous isatuximab for the treatment of multiple myeloma
On 8 June 2026, the European Commission approved the subcutaneous (under the skin) formulation of isatuximab (Sarclisa®) for use in all myeloma indications currently approved for the intravenous (IV) formulation of isatuximab. The newly approved subcutaneous formulation can be administered as a subcutaneous injection or using the CirCLIQ® on-body injector. This makes it the first…
Myeloma EHA 2026 preview
The European Hematology Association (EHA) 2026 Annual Congress, the largest haematology event in Europe, will take place from 11–14 June in Stockholm, Sweden. The congress will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma and AL amyloidosis. Myeloma Patients Europe (MPE) will be attending EHA to keep…
World Blood Cancer Day!
To mark World Blood Cancer Day on 28 May, we are highlighting the important work of our Polish member, the Carita Foundation and how they have collaborated with us to raise awareness of important issues with Polish policymakers. The Carita Foundation has today participated in a meeting of the Parliamentary Working Group on Oncology in the Polish Parliament. This meeting…
Join our EHA 2026 highlights webinar
To help patients and advocates digest the most important myeloma news from the European Hematology Association (EHA) 2026 Annual Congress, the largest haematology event in Europe, Myeloma Patients Europe (MPE) will host a webinar on Tuesday, 30 June at 17:00 CET. At this webinar you can expect clear explanations of the key research updates and…
New ways to administer daratumumab and isatuximab get positive recommendations from EMA
At the end of March, the Committee for Medicinal Products for Human Use (CHMP) announced two positive recommendations for new ways of administering the existing myeloma drugs daratumumab and isatuximab. Both drugs are monoclonal antibodies used in the treatment of myeloma. Both CHMP recommendations focus on subcutaneous injection, where a medication is injected into the…
- 31
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 1
- 2
- 3
- 4